Vivek Subbiah, MD, explains how patients with rare and common tumors can benefit from next generation sequencing (NGS)-based testing for NTRK gene fusions. He presents the case of a patient who benefited from precision medicine based on the detection of a NTRK1 fusion by comprehensive genomic profiling.
Audio PlayerFor the best experience using our website, we recommend that you upgrade to a newer version or use another web browser. A list of the most popular web browsers can be found below.
Click on an icon below to go to the download page or close this notice to continue with the current experience.